Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Carl Barrett

Showing results (151-160 of 210) with videos related to

Pageof 21
Sort By:
Nature Communications|February 27, 2023
Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancerJuliann Chmielecki, Jhanelle E Gray, Ying Cheng, et al.
JCO Precision Oncology|September 14, 2020
Mechanisms of Acquired Resistance to Savolitinib, a Selective MET Inhibitor in <i>MET</i>-Amplified Gastric CancerMelanie M Frigault, Aleksandra Markovets, Barrett Nuttall, et al.
Cancers|November 27, 2021
Homologous Recombination Repair Gene Mutation Characterization by Liquid Biopsy: A Phase II Trial of Olaparib and Abiraterone in Metastatic Castrate-Resistant Prostate CancerT Hedley Carr, Carrie Adelman, Alan Barnicle, et al.
Nature|March 14, 2008
SIRT6 is a histone H3 lysine 9 deacetylase that modulates telomeric chromatinEriko Michishita, Ronald A McCord, Elisabeth Berber, et al.
Gynecologic Oncology|November 7, 2021
Concordance of BRCA mutation detection in tumor versus blood, and frequency of bi-allelic loss of BRCA in tumors from patients in the phase III SOLO2 trialDarren R Hodgson, Jessica S Brown, Simon P Dearden, et al.
The Lancet. Oncology|June 3, 2014
Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trialJonathan Ledermann, Philipp Harter, Charlie Gourley, et al.
The American Journal of Clinical Nutrition|February 9, 2005
Effects of alcohol on insulin-like growth factor I and insulin-like growth factor binding protein 3 in postmenopausal womenJackie A Lavigne, David J Baer, Heather H Wimbrow, et al.
Nature Medicine|May 5, 2015
Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790MKenneth S Thress, Cloud P Paweletz, Enriqueta Felip, et al.
Nature Reviews. Drug Discovery|January 20, 2018
Impact of a five-dimensional framework on R&D productivity at AstraZenecaPaul Morgan, Dean G Brown, Simon Lennard, et al.
Cancer Research|November 17, 2005
Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovaryTomas Bonome, Ji-Young Lee, Dong-Choon Park, et al.
Pageof 21

Showing results (151-160 of 210) with videos related to

Sort By:
Pageof 21
Nature Communications|February 27, 2023
Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancerJuliann Chmielecki, Jhanelle E Gray, Ying Cheng, et al.
JCO Precision Oncology|September 14, 2020
Mechanisms of Acquired Resistance to Savolitinib, a Selective MET Inhibitor in <i>MET</i>-Amplified Gastric CancerMelanie M Frigault, Aleksandra Markovets, Barrett Nuttall, et al.
Cancers|November 27, 2021
Homologous Recombination Repair Gene Mutation Characterization by Liquid Biopsy: A Phase II Trial of Olaparib and Abiraterone in Metastatic Castrate-Resistant Prostate CancerT Hedley Carr, Carrie Adelman, Alan Barnicle, et al.
Nature|March 14, 2008
SIRT6 is a histone H3 lysine 9 deacetylase that modulates telomeric chromatinEriko Michishita, Ronald A McCord, Elisabeth Berber, et al.
Gynecologic Oncology|November 7, 2021
Concordance of BRCA mutation detection in tumor versus blood, and frequency of bi-allelic loss of BRCA in tumors from patients in the phase III SOLO2 trialDarren R Hodgson, Jessica S Brown, Simon P Dearden, et al.
The Lancet. Oncology|June 3, 2014
Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trialJonathan Ledermann, Philipp Harter, Charlie Gourley, et al.
The American Journal of Clinical Nutrition|February 9, 2005
Effects of alcohol on insulin-like growth factor I and insulin-like growth factor binding protein 3 in postmenopausal womenJackie A Lavigne, David J Baer, Heather H Wimbrow, et al.
Nature Medicine|May 5, 2015
Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790MKenneth S Thress, Cloud P Paweletz, Enriqueta Felip, et al.
Nature Reviews. Drug Discovery|January 20, 2018
Impact of a five-dimensional framework on R&D productivity at AstraZenecaPaul Morgan, Dean G Brown, Simon Lennard, et al.
Cancer Research|November 17, 2005
Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovaryTomas Bonome, Ji-Young Lee, Dong-Choon Park, et al.
Pageof 21